Skip to main content
. 2021 Jul 5;23:89. doi: 10.1186/s12968-021-00785-6

Table 1.

Baseline and cardiovascular magnetic resonance (CMR) characteristics of patients with and without inducible ischemia on vasodilator stress CMR (N = 1402)

All patients (N = 1402) No inducible ischemia (N = 988) Inducible ischemia (N = 414) p value
Age, years 69.5 ± 11.0 68.5 ± 10.7 72.0 ± 11.3 < 0.001
Males, n (%) 935 (66.7) 641 (64.9) 294 (71.0) 0.031
Body mass index, kg/m2 28.6 ± 6.3 28.8 ± 6.5 28.4 ± 5.8 0.288
Body surface index, m2 2.0 ± 0.3 2.0 ± 0.3 2.0 ± 0.2 0.056
Coronary risk factors, n (%)
 Diabetes mellitus 459 (32.7) 297 (30.1) 162 (39.1) 0.001
 Hypertension 807 (57.6) 542 (54.9) 265 (64.0) 0.002
 Obesitya 431 (30.7) 313 (31.7) 118 (28.5) 0.266
 Dyslipidemia 819 (58.4) 554 (56.1) 265 (64.0) 0.007
 Smoking 336 (24.0) 248 (25.1) 88 (21.3) 0.142
 Family history of CAD 391 (27.9) 268 (27.1) 123 (29.7) 0.358
Medical history of CVD, n (%)
 Known CAD 727 (51.9) 516 (52.2) 211 (51.0) 0.71
  History of PCI 442 (31.5) 336 (34.0) 106 (25.6) 0.002
  History of CABG 445 (31.7) 277 (28.0) 168 (40.6) < 0.001
  Known MI 340 (24.3) 246 (24.9) 94 (22.7) 0.42
 Peripheral atheroma 158 (11.3) 72 (7.3) 86 (20.8) < 0.001
 Ischemic stroke 54 (3.9) 39 (3.9) 15 (3.6) 0.892
 Pacemaker 7 (0.5) 4 (0.4) 3 (0.7) 0.428
 Renal failureb 20 (1.4) 14 (1.4) 6 (1.4) 1.000
 History of hospitalization for HF 52 (3.7) 42 (4.3) 10 (2.4) 0.133
Symptoms, n (%)
Symptomatic angina 706 (50.4) 415 (42.0) 291 (70.3) < 0.001
 Dyspnea 211 (15.0) 158 (16.0) 53 (12.8) 0.149
 High cardiovascular riskc 808 (57.6) 519 (52.5) 289 (69.8) < 0.001
 Ten-year risk for fatal CADd, % 2.5 (1.2–5.9) 2.1 (0.8–5.3) 3.3 (1.5–6.4) < 0.001
Indications to stress CMR, n (%)
 Inconclusive stress echocardiography 702 (50.1) 500 (50.6) 202 (48.8) 0.165
 Inconclusive SPECT 612 (43.7) 438 (44.3) 174 (42.0) 0.159
 Inconclusive exercise ECG testing 88 (6.3) 66 (6.7) 22 (5.3) 0.512
Cardiac rhythm, n (%)
 Sinus rhythm 1155 (82.4) 821 (83.1) 334 (80.7) 0.177
 Atrial fibrillation/supraventricular arrhythmias 247 (17.6) 217 (22.0) 30 (7.2) < 0.001
LV ejection fraction, % 50.4 ± 12.1 50.1 ± 11.9 51.2 ± 12.5 0.007
LV end-diastolic volume index, ml/m2 93.3 ± 31.2 94.8 ± 31.6 89.6 ± 30.1 0.004
LV end-systolic volume index, ml/m2 51.2 ± 26.1 52.5 ± 26.1 48.1 ± 26.0 0.004
LV mass, g/m2 73.9 ± 9.8 72.2 ± 9.8 78.7 ± 9.7 < 0.001
RV ejection fraction, % 63.6 ± 10.5 63.6 ± 10.5 63.5 ± 10.6 0.771
Presence of LGE, n (%) 556 (39.7) 422 (42.7) 134 (32.4) < 0.001
Presence of viability if LGE, n (%)e 178 (12.7) 117 (11.8) 61 (14.7) 0.163
Number of LGE segments if LGE 0.9 ± 1.3 1.0 ± 1.3 0.8 ± 1.4 0.09
Number of ischemic segments 0.7 ± 1.2 0.0 ± 0.0 2.3 ± 1.2 < 0.001
RPP at baseline, mmHg/beats/min 9.1 (7.5–10.1) 9.1 (7.5–10.1) 9.2 (7.6–10.4) 0.533
RPP at stress, mmHg/beats/min 10.8 (10.4–12.7) 10.8 (10.4–12.7) 11.4 (9.9–14.5) 0.175
CMR-related coronary revascularizationb, n (%) 323 (23.0) 0 (0) 323 (78.0) < 0.001
 By PCI 317 (22.6) 0 (0) 317 (76.6) < 0.001
 By CABG 6 (0.4) 0 (0) 6 (1.4) 0.004

Bold empasis means that the P value has reached statistical significance, with 2-tailed P value < 0.05

Values are n (%), mean ± SD, or median (interquartile range)

BMI body mass index, CABG coronary artery bypass graft, CAD coronary artery disease, CMR cardiovascular magnetic resonance, CVD cardiovascular disease, ECG electrocardiogram, HF heart failure, LGE late gadolinium enhancement, LV left ventricle, MI myocardial infarction, PCI percutaneous coronary intervention, RPP rate-pressure product (pressure mmHg × Heart rate bpm)/1000, SD standard deviation

aDefined by BMI ≥ 30 kg/m2

bDefined by glomerular filtration rate < 60 ml/min/1.73 m2

cDefined by Framingham Risk Score > 20% of risk of CAD at 10 years

dBased on a modified SCORE project (https://www.escardio.org/Education/Practice-Tools/CVD-prevention-toolbox/SCORE-Risk-Charts) that did not take into account the total cholesterol level [22, 23]

eDefined by the presence of LGE with < 50% transmurality